Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.56 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.42 |
| ▸ | CTH | P32929 | 1/20 | 0.40 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.39 |
| ▸ | MME | P08473 | 4/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.37 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.37 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9999987 | 0.87 | EGLN1 (0.62) | EGLN1PLA2G2AMAPTALDH1A1LMNA | |
| SCHEMBL27798283 | 0.84 | — | — | |
| SCHEMBL597184 | 0.77 | EGLN1 (0.58) | EGLN1PLA2G2AMAPTALDH1A1LMNA | |
| SCHEMBL17183911 | 0.77 | EGLN1 (0.41) | EGLN1PLA2G2AMAPTALDH1A1LMNA | |
| SCHEMBL11130677 | 0.77 | EGLN1 (0.46) | EGLN1PLA2G2AMAPTALDH1A1LMNA | |
| SCHEMBL7457741 | 0.77 | EGLN1 (0.52) | EGLN1PLA2G2AMAPTALDH1A1LMNA | |
| SCHEMBL10080192 | 0.77 | EGLN1 (0.52) | EGLN1PLA2G2AMAPTALDH1A1LMNA | |
| SCHEMBL6910661 | 0.77 | EGLN1 (0.52) | EGLN1PLA2G2AMAPTALDH1A1LMNA | |
| SCHEMBL11140818 | 0.75 | — | — | |
| SCHEMBL13401875 | 0.75 | EGLN1 (0.50) | EGLN1PLA2G2AMAPTALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 507 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | UNIV RAMOT (IL) | 2026-05-07 | — | — | US | claimed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | claimed |
| US-20250319119-A1 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | MASSACHUSETTS GEN HOSPITAL (US) | 2025-10-16 | — | — | US | claimed |
| EP-3936608-B1 | REPROGRAMMING CELLS | SCRIPPS RESEARCH INST (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250066735-A1 | PREPARATION METHOD OF MESENCHYMAL STEM CELL (MSC) AND APPLICATION THEREOF IN KNEE PRODUCT | GUANGDONG CELL BIOTECHNOLOGY CO. LTD (CN) | 2025-02-27 | — | — | US | claimed |
| EP-4512819-A2 | COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS | The General Hospital Corporation (US) | 2025-02-26 | — | — | EP | claimed |
| CN-118497122-B | Preparation method of mesenchymal stem cells and application of mesenchymal stem cells in knee joint products | 广东赛尔生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118497122-A | Preparation method of mesenchymal stem cells and application of mesenchymal stem cells in knee joint products | 广东赛尔生物科技有限公司 | 2024-08-16 | — | — | CN | claimed |
| WO-2024157019-A1 | PHD INHIBITORS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-08-02 | — | — | WO | claimed |
| EP-1451341-A4 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA FARBER CANCER INST INC (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040248139-A1 | Eit-6, a polypeptide encoded by an estrogen regulated gene | DANA-FARBER CANCER INSTITUTE, INC. | 2004-12-09 | — | — | US | claimed |
| EP-1451341-A2 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2004-09-01 | — | — | EP | claimed |
| WO-2004058252-A2 | ANTI-CANCER AGENTS COMPRISING ALKB INHIBITORS AND ALKYLATING AGENTS | ISIS INNOVATION LIMITED (GB) | 2004-07-15 | — | — | WO | claimed |
| WO-2003042363-A2 | EIT-6, A POLYPEPTIDE ENCODED BY AN ESTROGEN REGULATED GENE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2003-05-22 | — | — | WO | claimed |
| EP-0981549-B1 | USE OF AN INHIBITOR SUBSTANCE FOR THE IMPROVEMENT OF NEURONAL REGENERATION | NEURAXO BIOTEC GMBH (DE) | 2002-09-25 | — | — | EP | claimed |
| US-20020115598-A1 | METHOD FOR THE IMPROVEMENT OF NEURONAL REGENERATION | NEURAXO-BIOTEC GMBH (DE) | 2002-08-22 | — | — | US | claimed |
| EP-0981549-A1 | A METHOD FOR THE IMPROVEMENT OF NEURONAL REGENERATION | Müller, H.W., Prof. Dr. (DE) | 2000-03-01 | — | — | EP | claimed |
| WO-1998051708-A1 | A METHOD FOR THE IMPROVEMENT OF NEURONAL REGENERATION | MUELLER H W (DE) | 1998-11-19 | — | — | WO | claimed |
| EP-0878480-A1 | A method for the improvement of neuronal regeneration | Müller, H.W., Prof. Dr. (DE) | 1998-11-18 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | RNMT, TRMT1L, UPF1 | EGLN1 3552/4885PLA2G2A 2427/4885MAPT 1963/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | EGLN1 3/4885PLA2G2A 3128/4885MAPT 4473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.